Suppliers / Delpharm Montréal

Delpharm Montréal

France 2 duplicate records merged Updated 9 July 2026

Delpharm Montréal is a finished-dose manufacturer based in France. It appears in 24 regulatory filings across 6 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), MINSA (CR) and NCELS (KZ). Its GMP standing is certified by ANSM (FR), US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 1 September 2023 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
24
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
7 of 7 confirmed
EU GMP
0 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 1 September 2023 VAI US FDA
  • 17 January 2020 NAI US FDA
  • 8 December 2017 VAI US FDA
  • 2 September 2016 NAI US FDA
  • 31 January 2014 NAI US FDA
  • 16 September 2011 VAI US FDA
  • 7 July 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Quebec, United Arab Emirates Not on file
Canada, Canada 3002808099
Bretigny Sur Orge, France Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 15 None
MINSA (CR) 4 None
NCELS (KZ) 2 None
NPRA (MY) 1 None
DIGEMAPS (DO) 1 None
UZPHARM (UZ) 1 None
ANSM (FR) None 9
US FDA None 1
EMA None 1

Scale

Year Revenue Exports Destinations
2024 $21.2M Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Delpharm Montréal comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 1 September 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported